应用卡巴拉汀治疗轻到中重度阿尔茨海默病患者52周有效性研究(译文)
http://www.100md.com
DepartmentofNeurology;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSan
胆碱酯酶抑制剂|卡巴拉汀|临床试验|阿尔茨海默病
参见附件(58kb)。
DepartmentofNeurology;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;北京诺华制药有限公司 IndianaUniversitySchoolofMedicine;In Martin Farlow;RaviAnand;John Messina Jr;Richard Hartman;Jeffrey Veach
关键词:胆碱酯酶抑制剂;卡巴拉汀;临床试验;阿尔茨海默病
摘要:
DepartmentofNeurology;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;DepartmentsofMedicalAffairsCNSandStatistics;北京诺华制药有限公司 IndianaUniversitySchoolofMedicine;In Martin Farlow;RaviAnand;John Messina Jr;Richard Hartman;Jeffrey Veach
关键词:胆碱酯酶抑制剂;卡巴拉汀;临床试验;阿尔茨海默病
摘要:
您现在查看是摘要介绍页,详见CAJ附件(58kb)。